EU/3/15/1604

About

On 11 January 2016, orphan designation (EU/3/15/1604) was granted by the European Commission to Medpace Germany GmbH, Germany, for two allogeneic irradiated pancreatic tumour cell lines (also known as GVAX) for the treatment of pancreatic cancer.

The sponsorship was transferred to Aduro Biotech Holdings, Europe B.V., The Netherlands, in April 2016.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.

Key facts

Active substance
Two allogeneic irradiated pancreatic tumour cell lines
Disease / condition
Treatment of pancreatic cancer
Date of first decision
11/01/2016
Outcome
Withdrawn
EU designation number
EU/3/15/1604

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Aduro Biotech Holdings, Europe B.V.
Pivot Park RX 1101
Molenweg 79
5349 AC Oss
The Netherlands
Tel. +31 8 80 12 14 00
Fax +31 2 07 11 81 40

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
2 ratings